PHARMACEUTICAL INDUSTRY
Published on 18 Feb 2025
India is a global pharmaceutical powerhouse, renowned for its generic drug production and affordable healthcare solutions. As the world's largest provider of generic medicines and a significant vaccine supplier, it plays a vital role in global health security.
Locational Factors shaping the Industry
Large Domestic Market: Strong domestic demand for medicines, further boosted by generic drug initiatives.
Strategic Exports: Proximity to African and European markets on the west coast reduces transportation costs for generic drug exports.
Favourable Government Policies:
FDI: 100% FDI allowance attracts foreign investment.
IP Protection: Strong patent laws (e.g., Evergreening & Compulsory Licensing verdicts) benefit domestic companies.
Biotechnology & R&D Incentives: Government support for R&D fosters innovation.
Strong Infrastructure: Availability of power, transportation, and communication plays a crucial role, with most facilities concentrated on the west coast due to these advantages.
Skilled Workforce: The presence of a skilled labour force is a major locational factor, contributing to the industry's decentralization across the country.
Raw Material Access: Proximity to petrochemical hubs like Jamnagar (Gujarat) and Bombay High (Maharashtra) providing essential raw materials.
Capital Availability: The historical concentration of trade and capital in western India has traditionally fueled the pharmaceutical industry's growth there.
Challenges faced by the Industry
R&D Lag: Limited focus on research and development compared to other developed nations.
Example: India's pharmaceutical industry spends around 7-8% of its revenue on R&D, significantly lower than global pharma giants like Pfizer and Merck, which typically invest 15-20%.
Raw Material Dependence: Reliance on China for around 70% of Active Pharmaceutical Ingredients (APIs) makes the industry vulnerable.
Global Competition: Stiff competition from countries like China, Israel, and Japan, with accusations of patent violations from large players.
Quality Concerns: The presence of duplicate and potentially adulterated drugs raises concerns.
Example: The World Health Organization estimates that 10% of the global drug supply is counterfeit, with a significant portion originating from developing countries.
US Trade Watch List: Inclusion on the U.S. Priority Watch List creates uncertainty for Indian exports.
Prospects and need to promote the Industry
Cost Advantage: One of the world's lowest manufacturing costs (lower than US and nearly half of Europe) makes India a competitive producer.
Skilled Workforce: A readily available pool of skilled labour allows for industry growth and decentralization across the country.
Government Support: Promotion of traditional medicine (Ayurveda) and investment in R&D labs and Biotech parks fosters innovation and opens new avenues for drug development.
High Demand: Huge domestic and global demand for life-saving drugs, like those for diabetes and cardiovascular diseases, presents a significant growth opportunity. By 2020, India is expected to be among the top three pharmaceutical markets in terms of incremental growth.
Global Leader: India is the world's largest supplier of generic drugs, making it a key player in affordable medicine access.
Contract Research: Collaboration with international companies in Contract Research Organizations (CROs) expands service offerings and attracts foreign investment.